Is Skyrizi’s patent still valid, and what’s it protecting?
Skyrizi (risankizumab) is protected by a mix of patents that typically cover the drug substance/biologic, related formulations, manufacturing, and specific medical uses. Patent status depends on the jurisdiction (for example, U.S. vs. Europe) and on which specific patent (or patent family) you mean. Public patent-watch sources generally list multiple active patents or term extensions that can delay generic or biosimilar entry beyond the first filing date.
Because patent validity is patent-by-patent (and can change with licensing, expiration, or legal challenges), the practical question for most searches is whether any patent that blocks a biosimilar has expired or is still in force in a given country.
Are there any challenges to Skyrizi patents (invalidity or infringement)?
For high-revenue biologics like Skyrizi, companies seeking biosimilar approval frequently challenge patents on grounds such as non-infringement, lack of novelty, or obviousness. These disputes can play out in patent litigation and can also affect the timing of biosimilar launch through “stay” mechanisms tied to regulatory pathways.
If you are trying to assess “validity” in a concrete way, the most informative artifacts are: court dockets/decisions, which patents were asserted, and whether those patents were found valid, narrowed, or invalidated.
When would Skyrizi’s patent protection expire?
Skyrizi’s earliest patent expiries and any later protection (such as extensions, pediatric exclusivity, or additional method/formulation patents) determine the window for biosimilar launch in each market. Expiration can also be offset by:
- extra years from legal/statutory extensions tied to drug development timelines, and
- later-granted patents within the same family that claim additional aspects of the product.
To answer “when does it expire” precisely, you need the jurisdiction and the specific patent numbers being discussed by the biosimilar applicant or patent holder.
Can biosimilars enter before all Skyrizi patents expire?
Yes, depending on how the regulatory pathway and patent landscape line up. Even if some patents remain in force, a biosimilar may launch if it does not infringe the remaining enforceable claims or if those claims are invalidated/narrowed through litigation. Some launches occur while other patents are still pending or under appeal, because patent protection is claim-specific.
What matters for “validity” searches: which claims are being enforced?
Courts often do not treat an entire patent as “valid or invalid” in a single binary way. They can:
- invalidate specific claims,
- uphold others,
- or narrow claim scope (which changes whether a competitor’s product infringes).
So the most useful “validity” information usually comes from which claims survive and whether enforcement is still ongoing.
What to search for to verify Skyrizi patent validity yourself (fast)
If you want a definitive, up-to-date answer, search by:
- jurisdiction (U.S., EU, UK),
- Skyrizi patent numbers from a patent-listing or litigation summary,
- “risankizumab” plus the patent holder and a biosimilar applicant name,
- court outcomes (e.g., invalidity/infringement rulings),
- and the latest “status” fields from patent registers or litigation databases.
If you tell me the country (and whether you mean U.S. patents specifically), I can narrow the answer to the relevant patent set and explain what is still enforceable versus expired.
Key clarification needed to answer precisely
“Skyrizi patent validity” can mean different things:
1) Are Skyrizi patents still active right now in the U.S./EU?
2) Were specific Skyrizi patents found invalid in court?
3) Can a biosimilar launch despite pending patents?
Reply with the country (U.S. or Europe, for example) and any patent number (or the biosimilar name you’re comparing), and I’ll tailor the validity/expiration picture to that exact question.
Sources
I don’t have the provided patent documents or a specified patent listing in this chat, so I can’t cite specific Skyrizi patent numbers or case results yet.